Pharm D Solutions Recalls Sermorelin/Ipamorelin Powder Due to Sterility Concerns
Pharm D Solutions is recalling 179 vials of Sermorelin/Ipamorelin powder because the company cannot ensure the product is sterile.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text explicitly identifies the agency classification as Class II. According to the severity rubric, an FDA Class II recall is mapped to a score of 4 (Severe).
Plain-English summary
Pharm D Solutions, LLC is recalling 179 vials of Sermorelin/Ipamorelin 18 mg/15 mg Powder (NDC 69699-1759-18). The recall was initiated because the company lacks assurance of the product's sterility. The affected lot is 07272018:31, with a discard-by date of 1/23/2019.
The product was distributed nationwide. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Consumers and healthcare providers should stop using the affected product and contact Pharm D Solutions for further instructions or a refund.
The recalled product
- Product
- Sermorelin/Ipamorelin 18 mg/15 mg Powder, Pharm D Solutions, Houston, Texas --- NDC 69699-1759-18
- Manufacturer
- Pharm D Solutions, LLC
- Category
- Drug — Injectable Powder
- Hazard
- Affected units
- 179
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 07272018:31 Discard by: 1/23/2019
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 79 recalled by Pharm D Solutions, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 79 products in this recall →Related recalls
Same manufacturer · Pharm D Solutions, LLC
See all →- SeverePharm D Solutions Recalls Sermorelin/GHRP-2 &6 Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Sermorelin Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls B-Complex Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SevereFDA Recalls Ipamorelin Acetate Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Testosterone Cypionate Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- SeverePharm D Solutions Recalls Sermorelin/Ipamorelin Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Sermorelin Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SevereFDA Recalls Ipamorelin Acetate Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Sermorelin/GHRP-2 Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Sermorelin/GHRP-2 &6 Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePromise Pharmacy Recalls Ipamorelin and Sermorelin Injections Due to Sterility Concerns
FDA (Drugs) · 2019-02-20